Role of receptor-ligand system in giant cell tumor
Abstract
Expression of VEGF and its receptors and proliferative activities were studied in cells of giant cell tumor of the bone. Immuno-histochemical analysis was performed on 11 formalin-fixed, formalin-embedded samples of giant cell tumor of the bone. VEGF and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-l/KDR) was detected in all specimens and all cellular components such as reactive osteoclast-like giant cells and stromal cells. Ki-67 expression was limited to the mononuclear stromal cell component of the tumors. The high degree of expression Flk-1 and Flt-1 significantly correlated with high proliferative activity of the tumor (≥5 %) (p=0,031 for Flk-1 and p=0,048 for Flt-1). These results suggest that VEGF receptor-ligand system might play a role in the pathogenesis of giant cell tumor of the bone. The further research should help to explain a unique nature and cell interaction mechanisms of this tumor.
About the Authors
E. V. Stepanova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
E. R. Musaev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
E. A. Sushencov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
N. N. Petrovichev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
M. D. Aliev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
M. R. Lichinizer
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Abe Y., Yonemura K., Nishida K., Takagi K. Giant cell tumor of bone: analysis of proliferative cells by double-labeling immunohistochemistry with anti-proliferating cell nuclear antigen antibody and culture procedure. Nippon Seikeigeka Gakkai Zasshi. 1994, v. 68, p. 407-414.
2. Atkins G.J., Kostakis P., Vincent C. et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J. Bone Miner Res. 2006, v. 21, p. 1339-1349.
3. Barleon B., Sozzani S., Zhou D. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996. v. 87. p. 3336-3343.
4. Cheng J.C., Johnston J.O. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin. Orthop. Relat. Res. 1997, v. 338, p. 205-214.
5. Chuong R., Kaban L.B., Kozakewich H. Central giant cell lesions of thejaws: clinicopathologic study. J. Oral Maxillofac Surg. 1986, v. 44, p. 708-713.
6. Clauss M., Weich H., Breier G. et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications of functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 1996, v. 271, p. 17629-17634.
7. Ismail F.W., Shamsudin A.M., Wan Z. et al. Кi67 immunohistochemistry index in stage III giant cell tumor of the bone. J. Exp. Clin. Cancer Res. 2010, v. 12, p. 29-25.
8. Lau Y.S., Sabokbar A., Gibbons C.L. et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum. Pathol. 2005, v. 36. p. 945-954.
9. Liao T.S., Yurgelun M.B., Chang S.S. et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J. Orthop. Res. 2005, v. 23, p. 203-209.
10. Mills B.G., Frausto A. Cytokines expressed in multinucleated cells. Paget’s disease and giant cell tumors versus normalbone. Calcif Tissue Int. 1997, 61, p. 16-21.
11. Morgan T., Atkins G.J., Trivett M.K. et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappa-B. Am. J. Pathol. 2005, v. 167, p. 117-128.
12. Niida S., Kaku M., Amano H. et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 1999, v. 190, p. 293-298.
13. Robinson D., Einhorn T.A. Giant cell tumor of bone: a unique paradigm of stromal hemapoietic cellular interactions. J. Cell Biochem. 1994, v. 55, p. 300-303.
14. Robinson D., Segal M., Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis Pathobiology. 2002-2003, v. 70, p. 333-342.
15. Rosai J., Ackerman L.V. Bones and Joints. In Rosai J. (Ed): Surgical Pathology. Mosby, St. Louis. 2004, p. 2169-2172.
16. Roux S., Quinn J., Pichaud F. et al. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone. J. Cell Physiol. 1996, v. 168, p. 489-498.
17. Werner M. Giant cell tumor of bone: morphological, biological and histogenetical aspects. Int. Orthop. 2006, v. 30, p. 484-489.
18. Wülling M., Delling G., Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum. Pathol. 2003, v. 34 (10), p. 983-993.
19. Zheng M.H., Robbins P., Xu J. et al. The histogenesis of giant cell tumor of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol. 2001, v. 16, p. 297-307.
20. Zheng M.H., Xu J., Robbins P. et al. Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum. Pathol. 2000, v. 31, p. 804-812.
Review
For citations:
Stepanova E.V., Musaev E.R., Sushencov E.A., Petrovichev N.N., Aliev M.D., Lichinizer M.R. Role of receptor-ligand system in giant cell tumor. Bone and soft tissue sarcomas, tumors of the skin. 2010;(3):34-38. (In Russ.)
Views:
61
Email this article 
